CogState (CGS.AX) Akcia Kurs
CogState Kurs
Za posledných 19 rokov vzrástli tržby CogState o 20,0 % ročne a dosiahli 53,09 Milión USD. Zisk na akciu rástol o 8,5 % ročne za posledných 16 rokov. Pri CogState je čistá marža 19,1 % stúpla oproti 16,0 % pred niekoľkými rokmi. Pri dnešnej cene je dividendový výnos približne 1,12 %. Výplatný pomer je okolo 34 % zisku. Konsenzuálna 12-mesačná cieľová cena pre CogState je 2,15 USD, asi pod cenu o 15,5 %. Z 6 analytikov 5 odporúča nákup — celkový konsenzus je Kúpiť.
Cena akcie CogState
Tieto dáta cez Eulerpool API
100 000 požiadaviek/mes. zadarmo · bez karty
Akcia CogState a analýza akcií
Často kladené otázky o akcii CogState
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Analytici aktuálne stanovujú priemernú cieľovú cenu 2,15 USD pre akciu CogState (medián: 2,15 USD), teda -13,9 % voči poslednej cene. Konsenzus vychádza z 6 hodnotení.
7 analytikov aktuálne hodnotí akciu CogState: 6 odporúča kúpiť, 1 držať a 0 predať. Na 2026 analytici očakávajú, že CogState dosiahne tržby 128,65 Milión USD a zisk na akciu 0,09 USD.
Pri aktuálnom kurze sa akcia CogState obchoduje za 2,27 EUR (2,55 USD).
Akcia CogState (CGS.AX) je kótovaná na 2 burzách, okrem iného: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
Tržby očakávané od CogState sú 128,65 Milión USD. Táto hodnota je založená na aktuálnych finančných údajoch a odráža obchodnú výkonnosť spoločnosti.
Zisk očakávané od CogState je 16,22 Milión USD. Čistý zisk odráža ziskovosť spoločnosti po odpočítaní všetkých nákladov.
Pomer ceny k zisku (P/E) CogState je v súčasnosti 27,32. P/E pomer porovnáva aktuálnu cenu akcie s ziskom na akciu a pomáha investorom pochopiť ocenenie akcie CogState.
Pomer ceny k tržbám (P/S) CogState je v súčasnosti 3,45. P/S pomer porovnáva tržnú kapitalizáciu s ročnými tržbami a slúži ako metryka ocenenia akcie CogState.
Skóre kvality AlleAktien pre CogState je 6/10.
ISIN CogState je AU000000CGS8. ISIN (Medzinárodné číslo identifikácie cenného papiera) je globálne jedinečný identifikátor cenných papierov.
Ticker CogState je CGS.AX. Tento burzovný symbol sa používa na obchodovanie akcií CogState na burze.
CogState akcia
CogState Peer Group
CogState Ticker
CogState FIGI
Ďalšie kľúčové údaje a analýzy CogState v podrobnom prieskume
Naša analýza akcií spoločnosti CogState obsahuje dôležité finančné ukazovatele, ako sú tržby, zisk, P/E pomer, P/S pomer, EBIT, ako aj informácie o dividende. Okrem toho skúmame aspekty, ako sú akcie, trhová kapitalizácia, dlhy, vlastné imanie a záväzky spoločnosti CogState. Ak hľadáte podrobnejšie informácie k týmto témam, na našich podstránkach vám ponúkame podrobné analýzy: